Correlation between lung neoplasm and serum level of Osteopontin: A meta-analysis

Biomedical Reports

Volumn 4, Issue 5, 2016, Pages 567-572

  Li, Dan ^a   Qian, Wang ^a   Li, Ruo Ran ^a   Zhang, Jinghao ^a   Li, Ke ^a   Wu, Yanmin ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Lung neoplasm; Meta analysis; Osteopontin

Indexed keywords

OSTEOPONTIN;

ARTICLE; CLINICAL PRACTICE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME POLYMORPHISM; HUMAN; LINEAR REGRESSION ANALYSIS; LUNG TUMOR; META ANALYSIS; PROTEIN EXPRESSION; PUBLISHING; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

EID: 85016556587     PISSN: 20499434     EISSN: 20499442     Source Type: Journal    
DOI: 10.3892/br.2016.619     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J and Goldstraw P; International Staging Committee and Participating Institutions: The International Association for the Study of Lung Cancer Staging Project: Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4: 792-801, 2009.
3. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
4. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, et al: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11: 4646-4652, 2005.
5. Han SS, Lee SJ, Kim WJ, Ryu DR, Won JY, Park S and Cheon MJ: Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer. Tuberc Respir Dis (Seoul) 75: 104-110, 2013.
6. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK and Kim SK: Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57: 373-380, 2007.
7. Moszynski R, Szubert S, Szpurek D, Michalak S and Sajdak S: Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynaecol Res 39: 1518-1525, 2013.
8. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD, Miceli MC and Spencer MJ: Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 119: 1583-1594, 2009.
9. Cho HJ, Cho HJ and Kim HS: Osteopontin: A multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 11: 206-213, 2009.
10. Lund SA, Giachelli CM and Scatena M: The role of osteopontin in inflammatory processes. J Cell Commun Signal 3: 311-322, 2009.
11. Okyay K, Tavil Y, Sahinarslan A, Tacoy G, Turfan M, Sen N, Gurbahar O, Boyaci B, Yalcin R, Demirkan D, et al: Plasma osteopontin levels in prediction of prognosis in acute myocardial infarction. Acta Cardiol 66: 197-202, 2011.
12. Song G, Ouyang G, Mao Y, Ming Y, Bao S and Hu T: Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J Cell Mol Med 13 (8): 1706-1718, 2009.
13. Xu YY, Zhang YY, Lu WF, Mi YJ and Chen YQ: Prognostic value of osteopontin expression in breast cancer: A meta-analysis. Mol Clin Oncol 3: 357-362, 2015.
14. Yuan SM, Wang J, Huang HR and Jing H: Osteopontin expression and its possible functions in the aortic disorders and coronary artery disease. Rev Bras Cir Cardiovasc 26: 173-182, 2011.
15. Wang YD, Chen H, Liu HQ and Hao M: Correlation between ovarian neoplasm and serum levels of osteopontin: A meta-analysis. Tumour Biol 35: 11799-11808, 2014.
16. Kang CG, Han HJ, Lee HJ, Kim SH and Lee EO: Rho-associated kinase signaling is required for osteopontin-induced cell invasion through inactivating cofilin in human non-small cell lung cancer cell lines. Bioorg Med Chem Lett 25: 1956-1960, 2015.
17. Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT and Mælandsmo GM: Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer 13: 540, 2013.
18. Sun BS, Li Y, Zhang ZF, You J and Wang CL: Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg 96: 1943-1951, 2013.
19. Peng B, Wang YH, Huang Z, Feng SJ and Wang YS: Prognostic significance of osteopontin in patients with lung cancer: A meta-analysis. Int J Clin Exp Med 7: 4616-4626, 2014.
20. Yan CH, Lv M, Li H, Song X, Yan F, Cao S and Ren X: Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection. J Cancer Res Clin Oncol 141: 1371-1378, 2015.
21. Karapanagiotou EM, Terpos E, Dilana KD, Alamara C, Gkiozos I, Polyzos A and Syrigos KN: Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol 27: 332-338, 2010.
22. Zhou H, Wu T and Zhu Y: The clinical significance of serum osteopontin in diagnosis of lung cancer. J Radioimmunol 24: 458-459, 2011 (In Chinese).
23. Jackson D, White IR and Riley RD: Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 31: 3805-3820, 2012.
24. Peters JL, Sutton AJ, Jones DR, Abrams KR and Rushton L: Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680, 2006.
25. Zintzaras E and Ioannidis JP: HEGESMA: Genome search meta-analysis and heterogeneity testing. Bioinformatics 21: 3672-3673, 2005.
26. Song C: Clinical significance of determination of changes CEA, SA, OPN, and VEGF levels after operative in patients with lung cancer. Frontier Med 15: 75-76, 2014.
27. Qiu Y and Fu Z: Clinical significance of determination on serum levels of vascular endothelial growth factor per platelet count and osteopontin patients with locally advanced non-small cell lung cancer (unpublished PhD thesis). Hebei Medical University, Shijiazhuang, 734.2, 2012.
28. Xu C, Yu K and Wang Q: The levels and clinical significance of osteopontin in serum of patients with lung cancer. J Chin Physician 14: 179-181, 2012.
29. Karadag F, Gulen ST, Karul AB, Kilicarslan N, Ceylan E, Kuman NK and Cildag O: Osteopontin as a marker of weight loss in lung cancer. Scand J Clin Lab Invest 71: 690-694, 2011.
30. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S and Donington JS: Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 28: 936-941, 2010.
31. Yin M and Zhang J: Study on OPN levels of serum in non-small cell lung cancer. Ningxia Med J 31: 679-680, 2009.
32. Dong S, Shao Z, Pan Y, Dai J and Chen G: The clinical significance of detection of serum osteopontin in patient with lung cancer. Mod J Integr Tradit Chin West Med 17: 3740-3741, 2008.
33. Weng W and Fu C: Value of serum osteopontin determination in patient with lung carcinoma. Lab Med Clin 4: 1025-1026, 2007.
34. Fedarko NS, Jain A, Karadag A, Van Eman MR and Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060-4066, 2001.
35. Chambers AF and Vanderhyden BC: Ovarian cancer biomarkers in urine. Clin Cancer Res 12: 323-327, 2006.
36. Lin CK, Chao TK, Lai HC and Lee HS: LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. Am J Clin Pathol 137: 971-977, 2012.
37. Yu TT, Han ZG, Shan L, Tao J, Zhang T, Yuan SF and Shen HL: Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density. Asian Pac J Cancer Prev 15: 29-32, 2014.
38. Štemberger C, Matušan-Ilijaš K, Avirović M, Bulat-Kardum L, Ivančić A, Jonjić N and Lučin K: Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma. Acta Histochem 116: 222-229, 2014.
39. Sun BS, You J, Li Y, Zhang ZF and Wang CL: Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis. Chin Med J (Engl) 126: 1683-1688, 2013.
40. Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ, Ling XL and Ma SC: The prognostic value of osteopontin expression in non-small cell lung cancer: A meta-analysis. J Mol Histol 45: 533-540, 2014.